Floatz logo

[99mTc]Tc-HYNIC-FAPI

Lung Cancer (Locally Advanced or Metastatic)

Tomsk National Research Medical Center of the Russian Academy of SciencesPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

303 Active assets in the Lung Cancer (Locally Advanced or Metastatic) cohort.

Asset / SponsorPhaseRating
Carboplatin
SystImmune Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
University of Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

[99mTc]Tc-HYNIC-FAPI is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →